Ratings by UBS (Michael Yee)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/17/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 7/6/2026 | Revolution | RVMD | Maintain | Buy (Buy) |
|
Details | ||
| 7/1/2026 | Oruka Therapeutics | ORKA | Maintain | Buy (Buy) |
|
Details | ||
| 6/29/2026 | Viridian Therapeutic | VRDN | Maintain | Buy (Buy) |
|
Details | ||
| 6/23/2026 | Apogee Therapeutics Inc | APGE | Downgrade | Neutral (Buy) |
90.38 (134.17) |
48.45% | Details | |
| 6/16/2026 | Denali Therapeutics Inc. | DNLI | Maintain | Buy (Buy) |
|
Details | ||
| 6/15/2026 | Jade Biosciences | JBIO | New Coverage | Buy (N/A) |
16.08 (19.70) |
22.51% | Details | |
| 6/9/2026 | Revolution | RVMD | Maintain | Buy (Buy) |
|
Details | ||
| 5/28/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (Buy) |
|
Details | ||
| 5/27/2026 | Pfizer | PFE | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/26/2026 | Moderna | MRNA | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/13/2026 | AnaptysBio | ANAB | Maintain | Buy (Buy) |
|
Details | ||
| 5/4/2026 | Moderna | MRNA | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/28/2026 | Oruka Therapeutics | ORKA | Maintain | Buy (Buy) |
|
Details | ||
| 4/22/2026 | Biogen | BIIB | Upgrade | Buy (Neutral) |
183.34 (205.61) |
12.15% | Details | |
| 4/21/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 4/21/2026 | AnaptysBio | ANAB | Maintain | Buy (Buy) |
|
Details | ||
| 4/21/2026 | First Tracks Biotherapeutics | TRAX | New Coverage | Buy (N/A) |
26.93 (41.85) |
55.4% | Details | |
| 4/20/2026 | Merck | MRK | Maintain | Buy (Buy) |
|
Details | ||
| 4/13/2026 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 4/13/2026 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 4/13/2026 | Amgen | AMGN | Maintain | Buy (N/A) |
|
Details | ||
| 4/6/2026 | Oruka Therapeutics | ORKA | Maintain | Buy (Buy) |
|
Details | ||
| 3/31/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 3/27/2026 | Kodiak Sciences Inc. | KOD | Maintain | Buy (Buy) |
|
Details | ||
| 3/18/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 3/17/2026 | Schrodinger | SDGR | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/17/2026 | AnaptysBio | ANAB | Maintain | Buy (N/A) |
|
Details | ||
| 3/6/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (Buy) |
|
Details | ||
| 3/3/2026 | Nuvation Bio Inc | NUVB | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/27/2026 | Revolution | RVMD | New Coverage | Buy (N/A) |
103.24 (183.86) |
78.09% | Details | |
| 2/25/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 2/24/2026 | MBX Biosciences Inc | MBX | Maintain | Buy (Buy) |
|
Details | ||
| 2/24/2026 | Arcellx Inc. | ACLX | Downgrade | Neutral (Buy) |
64.11 (115.07) |
79.49% | Details | |
| 2/18/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 2/17/2026 | Galecto | GLTO | New Coverage | Buy (N/A) |
29.12 (28.69) |
-1.48% | Details | |
| 2/10/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 2/5/2026 | Abbvie | ABBV | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/2/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 1/15/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 1/13/2026 | Abbvie | ABBV | Maintain | Neutral (Neutral) |
|
Details | ||
| 1/12/2026 | Merck | MRK | Maintain | Buy (Buy) |
|
Details | ||
| 1/12/2026 | AnaptysBio | ANAB | Maintain | Buy (Buy) |
|
Details | ||
| 1/8/2026 | Ventyx Biosciences Inc | VTYX | Downgrade | Neutral (Buy) |
10.05 (14.00) |
39.3% | Details | |
| 1/7/2026 | Abbvie | ABBV | New Coverage | Neutral (N/A) |
220.18 (263.20) |
19.54% | Details | |
| 1/7/2026 | Biogen | BIIB | New Coverage | Neutral (N/A) |
174.63 (183.34) |
4.99% | Details | |
| 1/7/2026 | Bristol-Myers Squibb Co. | BMY | New Coverage | Buy (Neutral) |
53.06 (63.60) |
19.86% | Details | |
| 1/7/2026 | Gilead Sciences | GILD | New Coverage | Buy (Neutral) |
118.30 (134.32) |
13.54% | Details | |
| 1/7/2026 | Eli Lilly | LLY | New Coverage | Buy (N/A) |
1041.51 (1220.66) |
17.2% | Details | |
| 1/7/2026 | Apogee Therapeutics Inc | APGE | New Coverage | Buy (N/A) |
77.51 (90.38) |
16.6% | Details | |
| 1/7/2026 | Allogene | ALLO | New Coverage | Buy (N/A) |
1.35 (1.66) |
22.96% | Details | |
| 1/7/2026 | Zai Lab | ZLAB | New Coverage | Buy (N/A) |
18.09 (18.62) |
2.93% | Details | |
| 1/7/2026 | Ventyx Biosciences Inc | VTYX | New Coverage | Buy (N/A) |
7.82 (10.05) |
28.52% | Details | |
| 1/7/2026 | Viridian Therapeutic | VRDN | New Coverage | Buy (N/A) |
30.20 (19.51) |
-35.4% | Details | |
| 1/7/2026 | Scholar Rock | SRRK | New Coverage | Buy (N/A) |
42.76 (49.37) |
15.46% | Details | |
| 1/7/2026 | Schrodinger | SDGR | New Coverage | Neutral (N/A) |
18.50 (15.29) |
-17.35% | Details | |
| 1/7/2026 | SAB Biotherapeutics | SABS | New Coverage | Buy (N/A) |
3.74 (3.45) |
-7.75% | Details | |
| 1/7/2026 | Oruka Therapeutics | ORKA | New Coverage | Buy (N/A) |
26.88 (90.45) |
236.5% | Details | |
| 1/7/2026 | Olema Pharmaceuticals | OLMA | New Coverage | Buy (N/A) |
25.10 (11.62) |
-53.71% | Details | |
| 1/7/2026 | Nuvation Bio Inc | NUVB | New Coverage | Neutral (N/A) |
8.59 (6.69) |
-22.12% | Details | |
| 1/7/2026 | MBX Biosciences Inc | MBX | New Coverage | Buy (N/A) |
29.31 (60.06) |
104.91% | Details | |
| 1/7/2026 | Kodiak Sciences Inc. | KOD | New Coverage | Buy (N/A) |
25.00 (40.29) |
61.16% | Details | |
| 1/7/2026 | Inventiva SA | IVA | New Coverage | Buy (N/A) |
4.60 (4.64) |
0.87% | Details | |
| 1/7/2026 | Immunocore Holdings | IMCR | New Coverage | Buy (N/A) |
32.75 (33.51) |
2.32% | Details | |
| 1/7/2026 | Ideaya Biosciences | IDYA | New Coverage | Buy (N/A) |
34.94 (36.16) |
3.49% | Details | |
| 1/7/2026 | Denali Therapeutics Inc. | DNLI | New Coverage | Buy (N/A) |
16.02 (24.05) |
50.12% | Details | |
| 1/7/2026 | Cogent | COGT | New Coverage | Buy (N/A) |
34.26 (40.67) |
18.71% | Details | |
| 1/7/2026 | Beam Therapeutics Inc | BEAM | New Coverage | Neutral (N/A) |
26.84 (26.29) |
-2.05% | Details | |
| 1/7/2026 | AnaptysBio | ANAB | New Coverage | Buy (N/A) |
43.20 (52.11) |
20.63% | Details | |
| 1/7/2026 | Aligos Therapeutics Inc. | ALGS | New Coverage | Buy (N/A) |
8.41 (4.25) |
-49.46% | Details | |
| 1/7/2026 | Arcellx Inc. | ACLX | New Coverage | Buy (N/A) |
61.83 (64.11) |
3.69% | Details | |
| 1/7/2026 | Pfizer | PFE | New Coverage | Neutral (N/A) |
25.17 (25.25) |
0.32% | Details | |
| 1/6/2026 | Amgen | AMGN | New Coverage | Buy (N/A) |
320.72 (393.10) |
22.57% | Details |
